Next 10 |
Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC Lead program, a proprietary long-acting GLP-1 receptor agonist, starting Phase 2 trial for Short Bowel Syndrome (SBS), an underserved, orphan condition Continued Phase 3 trial of larazotide; first and on...
RALEIGH, NC / ACCESSWIRE / March 20, 2020 / Innovate Biopharmaceuticals, Inc. (the "Company" or "Innovate") (NASDAQ:INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that it has filed its 2019 Annual Report on Form...
Israeli Regulatory Approvals Appear on Track for Late March 2020 to Allow Closing of the Merger RALEIGH, NC / ACCESSWIRE / March 11, 2020 / Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune a...
Highlighting Larazotide's Effect across the Gut-Vascular Barrier - a Fundamental Disease Mechanism in a Variety of Autoimmune and Inflammatory Diseases RALEIGH, NC / ACCESSWIRE / February 19, 2020 / Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical-stage...
Closing of this transformative transaction expected in early Q2 2020 upon completion of remaining closing conditions and receipt of regulatory approval in Israel RALEIGH, NC / ACCESSWIRE / February 18, 2020 / Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT - "Innovate"), a clinical stag...
TEL AVIV, Israel and RICHMOND, Calif. , Nov. 13, 2019 /PRNewswire/ -- RDD Pharma, Ltd. ("RDD"), a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter of intent ("LOI") to acquire Naia Rare Diseases ("Naia"), a biopharm...
Pfenex (NYSEMKT: PFNX ) +13% as FDA OKs Pfenex Forteo biosimilar. More news on: Pfenex Inc., Mereo BioPharma Group plc, Livongo Health, Inc., Stocks on the move, Read more ...
Deep Clinical-Stage Pipeline Combined With World-Class Leadership Team OrbiMed Advisors LLC to Lead a Concurrent Capital Raise 9 Meters Biopharma, Inc. Will Be the New Name of the Combined NASDAQ-Listed Public Company Conference Call on October 7, 2019 at 8:00 a.m. EDT / 5:0...
CeD LA 3001 trial doses first patient in historic Phase 3 celiac disease trial RALEIGH, N.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics fo...
Innovate Biopharmaceuticals (NASDAQ: INNT ): Q2 GAAP EPS of -$0.13 in-line. More news on: Innovate Biopharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Innovate Biopharmaceuticals Inc. Company Name:
INNT Stock Symbol:
NASDAQ Market:
Innovate Biopharmaceuticals Inc. Website:
Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC Lead program, a proprietary long-acting GLP-1 receptor agonist, starting Phase 2 trial for Short Bowel Syndrome (SBS), an underserved, orphan condition Continued Phase 3 trial of larazotide; first and on...
RALEIGH, NC / ACCESSWIRE / March 20, 2020 / Innovate Biopharmaceuticals, Inc. (the "Company" or "Innovate") (NASDAQ:INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that it has filed its 2019 Annual Report on Form...
Israeli Regulatory Approvals Appear on Track for Late March 2020 to Allow Closing of the Merger RALEIGH, NC / ACCESSWIRE / March 11, 2020 / Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune a...